It’s clear that the biotech sector’s potential is far from being fully realized, especially when companies like Mesoblast are breaking new ground. Mesoblast is not just another biotech company; it is ...

Approximately 50% develop aGvHD and almost half of those do not respond to steroids ... inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The ...

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast ...

An itch can drive you absolutely crazy, but there are times when scratching only makes it worse—throwing your body's ...